Skip to Content
Merck
  • Glycine antagonist action of 1-aminocyclobutane-1-carboxylate (ACBC) in Xenopus oocytes injected with rat brain mRNA.

Glycine antagonist action of 1-aminocyclobutane-1-carboxylate (ACBC) in Xenopus oocytes injected with rat brain mRNA.

European journal of pharmacology (1989-08-22)
G B Watson, M A Bolanowski, M P Baganoff, C L Deppeler, T H Lanthorn
ABSTRACT

ACBC has been reported to have the binding profile of an antagonist at the glycine site of the NMDA receptor. In Xenopus oocytes injected with rat brain mRNA, we have confirmed the antagonist action of ACBC on NMDA responses. ACBC and HA-966, a known glycine antagonist, blocked NMDA responses in a non-competitive manner and blocked the potentiation of NMDA responses by glycine in a competitive manner. We conclude that ACBC blocks NMDA responses via a competitive interaction at the glycine modulatory site.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1-Amino-1-cyclobutanecarboxylic acid, 97%